{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T07:28:26Z","timestamp":1782458906123,"version":"3.54.5"},"reference-count":12,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2002,12,1]],"date-time":"2002-12-01T00:00:00Z","timestamp":1038700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":6246,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2002,12]]},"DOI":"10.1093\/annonc\/mdf350","type":"journal-article","created":{"date-parts":[[2002,11,27]],"date-time":"2002-11-27T05:22:10Z","timestamp":1038374530000},"page":"1948-1950","source":"Crossref","is-referenced-by-count":98,"title":["Stevens\u2013Johnson syndrome after treatment with rituximab"],"prefix":"10.1016","volume":"13","author":[{"given":"S.","family":"Lowndes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Darby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Mead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdf350_bb0010","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1182\/blood.V63.6.1424.1424","article-title":"Expression of human B-cell associated antigens in leukaemias and lymphomas: a model of human B-cell differentiation","volume":"63","author":"Anderson","year":"1984","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdf350_bb0015","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1054\/bjoc.2001.2127","article-title":"Rituximab: mechanisms and applications","volume":"85","author":"Johnson","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdf350_bb0020","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD 20 monoclonal antibody therapy for relapsed indolent lymphoma","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf350_bb0025","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP chemotherapy alone in elderly patients with diffuse large B cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdf350_bb0030","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1046\/j.1365-2141.2000.01965.x","article-title":"A UK multicentre phase II study of rituximab in patients with follicular lymphoma, with PCR monitoring of molecular response","volume":"109","author":"Foran","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdf350_bb0035","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1200\/JCO.1999.17.6.1851","article-title":"Single agent monoclonal antibody efficacy in bulky non-Hodgkin\u2019s lymphoma","volume":"17","author":"Davis","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf350_bb0040","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin\u2019s lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdf350_bb0045","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1023\/A:1008389119525","article-title":"Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin\u2019s lymphoma","volume":"10","author":"Piro","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdf350_bb0050","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1200\/JCO.2001.19.8.2153","article-title":"Rituximab using a thrice weekly dosing schedule in B-cell chronic lyphocytic leukaemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity","volume":"19","author":"Byrd","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf350_bb0055","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1056\/NEJM200109273451315","article-title":"Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder","volume":"345","author":"Suzan","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdf350_bb0060","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1385\/MO:18:2:141","article-title":"Rituximab (Mabthera, Rituxan) in patients with recurrent indolent lymphoma: evaluation of safety and efficacy in a multicentre study","volume":"18","author":"Walewski","year":"2001","journal-title":"Med Oncol"},{"key":"10.1093\/annonc\/mdf350_bb0065","series-title":"Oxford Textbook of Medicine","author":"Weatherall","year":"1996"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419472190?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419472190?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/13\/12\/1948\/348575\/mdf350.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T06:55:11Z","timestamp":1582181711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419472190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,12]]},"references-count":12,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2002,12]]}},"alternative-id":["S0923753419472190"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdf350","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2002,12]]}}}